SG Americas Securities LLC Invests $393,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

SG Americas Securities LLC purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 45,187 shares of the biopharmaceutical company's stock, valued at approximately $393,000.

A number of other hedge funds have also bought and sold shares of the business. Amalgamated Bank grew its stake in Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 1,481 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in Ocular Therapeutix by 39.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,531 shares of the biopharmaceutical company's stock worth $105,000 after buying an additional 3,257 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Ocular Therapeutix by 36.9% during the 2nd quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company's stock valued at $119,000 after buying an additional 4,695 shares in the last quarter. Atlas Capital Advisors LLC bought a new stake in shares of Ocular Therapeutix during the 2nd quarter worth $34,000. Finally, Essex Investment Management Co. LLC lifted its holdings in shares of Ocular Therapeutix by 1.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 376,200 shares of the biopharmaceutical company's stock worth $3,423,000 after acquiring an additional 5,828 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

OCUL has been the topic of a number of analyst reports. Piper Sandler reiterated an "overweight" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Friday, June 21st. Scotiabank started coverage on Ocular Therapeutix in a report on Wednesday. They set a "sector outperform" rating and a $22.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of Ocular Therapeutix in a report on Wednesday. TD Cowen cut Ocular Therapeutix from a "strong-buy" rating to a "hold" rating in a research note on Friday, June 21st. Finally, Robert W. Baird dropped their price target on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.57.

Ocular Therapeutix Stock Up 2.2 %

Shares of NASDAQ OCUL traded up $0.24 on Friday, reaching $11.33. 712,986 shares of the company's stock traded hands, compared to its average volume of 1,956,606. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. The business's 50 day simple moving average is $8.96 and its two-hundred day simple moving average is $7.44. Ocular Therapeutix, Inc. has a 12 month low of $2.00 and a 12 month high of $11.58. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -8.21 and a beta of 1.29.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.04). Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The company had revenue of $16.40 million for the quarter, compared to analysts' expectations of $15.85 million. During the same quarter in the previous year, the firm posted ($0.27) EPS. The firm's quarterly revenue was up 7.9% compared to the same quarter last year. As a group, equities research analysts forecast that Ocular Therapeutix, Inc. will post -1.02 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.